-

Zai Lab Announces Participation in Investor Conferences in June 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in June 2025:

Jefferies Global Healthcare Conference
Fireside Chat: Wednesday, June 4, 2025, 10:30 a.m. EST
Webcast Link: https://wsw.com/webcast/jeff319/zlab/1845848
Location: New York, NY

Goldman Sachs 46th Annual Healthcare Conference
Time: Monday, June 9, 2025
Location: Miami, FL

Scotiabank Third Annual Healthcare Canadian Investor Day
Time: Tuesday, June 17, 2025
Location: Toronto, Canada

A live webcast of the fireside chat will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replay will be available for up to 90 days following the completion of the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.X.com/ZaiLab_Global.

Contacts

For more information, please contact:
Investor Relations:
Christine Chiou / Lina Zhang
+1 (917) 886-6929 / +86 136 8257 6943
christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media:
Shaun Maccoun / Xiaoyu Chen
+1 (857) 270-8854 / +86 185 0015 5011
shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Industry:

Zai Lab Limited

NASDAQ:ZLAB
Release Versions
English

Contacts

For more information, please contact:
Investor Relations:
Christine Chiou / Lina Zhang
+1 (917) 886-6929 / +86 136 8257 6943
christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media:
Shaun Maccoun / Xiaoyu Chen
+1 (857) 270-8854 / +86 185 0015 5011
shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

More News From Zai Lab Limited

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for COBENFY® (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. COBENFY is the first schizophrenia therapy with a novel mechanism of action approved in over 70 years [1], offering a fundamentally new approach to treating schizophrenia. By selectively activating M...

Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified and advanced internally by Zai Lab’s discovery team, targets both IL-13 and IL-31 pathways with an extend...

Zai Lab Announces Updates to China’s National Reimbursement Drug List

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA): VYVGART® (efgartigimod alfa injection) is renewed for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive; NUZYRA® (omadacycl...
Back to Newsroom